This special emphasis panel reviews applications focused on early small molecule drug discovery that typically involve high-throughput (HTS) assay development; primary screen implementation; hit validation; hit prioritization; and hit-to-lead optimization. Primary screening assays may be target-, pathway-, phenotype-, or fragment-based. Drug discovery can involve novel small molecules, immunomodulators, etc.
The List of Reviewers lists all present, whether standing members or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.
- Target-based biochemical or cellular assays that measure activities of enzymes, receptor-ligand binding, protein-protein interactions, ion channels, transporters, nuclear receptors and other transcription factors, and other new targets emerging from genetic and proteomic research in model systems and in human diseases;
- Cell- or organism-based assays that detect phenotypic changes that may involve unidentified molecular targets;
- Non-traditional targets of interest such as nucleic acids, protein folding, polymorphic gene products, post-transcriptional editing or gene splicing factors, and protein or RNA stabilizers.
Shared Interests and Overlaps
There are shared interests with Drug Discovery and Mechanisms of Antimicrobial Resistance (DDR) and ZRG1 IDM (82) in the area of antimicrobial, antifungal, and antiparasitic drug discovery and development. Applications that focus on identifying anti-infective targets, molecular mechanisms of action, and the development of lead compounds for anti-infective therapeutics may be assigned to DDR or ZRG1 IDM (82). Applications that focus on developing novel high throughput screens for small molecule hits and immunotherapeutics may be assigned to ZRG1 BST-F (55).
• There are shared interests with Drug Discovery and Molecular Pharmacology (DMP) in the area of cancer drug discovery. Applications that focus on identifying cancer targets, molecular mechanisms of action, developing lead compounds for cancer therapeutics may be assigned to DMP. Applications that focus on high throughput screens to identify small molecule hits, structure-activity-relation assay development, analog synthesis, and lead optimization for anti-cancer agents or cancer immunomodulators may be assigned to ZRG1 BST-F (55)